AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23973
Drug: Oxypertine 30
RxNorm normalized name: oxypertine
DrugBank: Oxypertine (DB13403)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxypertine 30 mg daily
Trial: 23973
Drug: Oxypertine 60
RxNorm normalized name: oxypertine
DrugBank: Oxypertine (DB13403)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxypertine 60 mg daily
Trial: 25879932
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy (CBT) delivered by psychologists with usual care
Trial: 20569223
Drug: Intravenous sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sodium valproate, loading dose of 900-1200 mg
Trial: 14963702
Drug: Dexamethasone (DEX)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DEX) 0.3 mg/kg per day for 3 days + 2 g/kg IVIG over 4 to 5 days
Trial: 14963702
Drug: Control group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: 2 g/kg IVIG over 4 to 5 days + higher dose acetylsalicylic acid
Trial: 11588947
Drug: 0.05 mg
RxNorm normalized name: biotin 0.05 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg transdermal estradiol twice weekly
Trial: 11588947
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg oral conjugated estrogen daily with 2.5 mg oral medroxyprogesterone acetate daily
Trial: 11588947
Drug: Transdermal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal therapy
Trial: 7798545
Drug: Azelastine 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine 0.1% (1 spray [0.12 mg] per nostril every 12 hours, 2 sprays per nostril every 12 hours, or 2 sprays per nostril once daily)
Trial: 7798545
Drug: Chlorpheniramine maleate
RxNorm normalized name: Chlorpheniramine Maleate
DrugBank: Chlorpheniramine (DB01114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine maleate (12 mg twice daily)
Trial: 2647645
Drug: reserpine, prazosin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: reserpine, prazosin, indapamide, atenolol (separately or in combination)
Trial: 825133
Drug: Methaqualone hydrochloride
RxNorm normalized name: Methaqualone hydrochloride
DrugBank: Methaqualone (DB04833)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methaqualone hydrochloride (400 mg)
Trial: 825133
Drug: Methaqualone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methaqualone (20 and 30 mg/kg body weight) in monkeys
Trial: 31403168
Drug: Cognitive and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive and behavioral therapy for insomnia (CBT-i)
Trial: 29095305
Drug: Direct intramuscular
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct intramuscular injection of MSCs (1*10 cells in 1 mL of 0.9% saline)
Trial: 29095305
Drug: Placebo-controlled group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-controlled group (1 mL of 0.9% saline)
Trial: 26465872
Drug: Statins +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statins + Amlodipine + Renin-Angiotensin-Aldosterone System Inhibitors (Benazepril or Losartan)
Trial: 26465872
Drug: Amlodipine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine + Renin-Angiotensin-Aldosterone System Inhibitors (Benazepril or Losartan) without Statins
Trial: 19190515
Drug: Investigational arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Investigational arm (first-line chemotherapy)
Trial: 19190515
Drug: Reference arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference arm (first-line chemotherapy)
Trial: 12677732
Drug: Taste strips
RxNorm normalized name: 60 Second Taste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taste strips impregnated with different taste solutions (four concentrations each for sweet, sour, salty, and bitter)
Trial: 9268956
Drug: 20 mg.kg-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg.kg-1 dose of powdered aspirin
Trial: 9268956
Drug: Placebo (water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (water and Kool-Aid mixture without aspirin)
Trial: 27898699
Drug: Caregivers' physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caregivers' physical access to SMC medication
Trial: 20128827
Drug: Implant stability
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein, A, recombinant, stabilized / respiratory syncytial virus pre-fusion F protein, B, recombinant, stabilized Injection [Abrysvo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant stability quotient (ISQ) measured in buccolingual direction
Trial: 20128827
Drug: Implant stability
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein, A, recombinant, stabilized / respiratory syncytial virus pre-fusion F protein, B, recombinant, stabilized Injection [Abrysvo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant stability quotient (ISQ) measured in mesiodistal direction
Trial: 11665796
Drug: 800,000 units
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800,000 units of intravenous monteplase followed by rescue PTCA
Trial: 9628067
Drug: Interleukin-2 (IL-2)
RxNorm normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-2 (IL-2) administered subcutaneously at a dosage of 9,000,000 U.I. b.i.d. for three days before surgery
Trial: 8166943
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg daily from mean gestational age of 17.7 weeks
Trial: 23747824
Drug: G-Bond (GB;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-Bond (GB; GC)
Trial: 19768649
Drug: Fosfomycin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosfomycin (3 g single dose)
Trial: 19768649
Drug: Amoxicillin-clavulanate (7-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate (7-day regimen)
Trial: 17053340
Drug: Self-exposure therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-exposure therapy (4 weeks)
Trial: 8458248
Drug: Ceftriaxone (CFX)
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (CFX) plus amikacin (single daily doses)
Trial: 8458248
Drug: Ceftriaxone (CFX)
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (CFX) plus amikacin (divided in three doses)
Trial: 31464063
Drug: Faster insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Faster insulin aspart
Trial: 31464063
Drug: Standard insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard insulin aspart
Trial: 11243631
Drug: Anti-CD3 antibodies
RxNorm normalized name: Anti-CD3
DrugBank: Muromonab (DB00075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-CD3 antibodies (1 microg/ml)
Trial: 11243631
Drug: Phytohemagglutinin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytohemagglutinin (10 microg/ml)
Trial: 11243631
Drug: Staphylococcal enterotoxin
RxNorm normalized name: Staphylococcal enterotoxin B specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Staphylococcal enterotoxin A (0.1 microg/ml)
Trial: 11243631
Drug: Tuberculin purified
RxNorm normalized name: Tuberculin Purified Protein Derivative
DrugBank: Tuberculin purified protein derivative (DB11601)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tuberculin purified protein derivative (10 microg/ml)
Trial: 8455962
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of pethidine
Trial: 3513569
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (10 mg/day) for 4 months
Trial: 3513569
Drug: Control medications
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Dial Dandruff Control]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control medications
Trial: 3513569
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid treatment
Trial: 24351527
Drug: Standard VTE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard VTE prophylaxis (5,000 U low‐molecular‐weight heparin daily)
Trial: 24351527
Drug: TEG‐guided prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEG‐guided prophylaxis (up to 10,000 U low‐molecular‐weight heparin daily)
Trial: 16176140
Drug: Cassia tora
RxNorm normalized name: Padang cassia oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cassia tora fiber supplement (2 g of soluble fiber, 200 mg of alpha-tocopherol, 500 mg of ascorbic acid, 300 mg of maltodextrin)
Trial: 16176140
Drug: Cassia tora
RxNorm normalized name: Padang cassia oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cassia tora fiber supplement
Trial: 8690639
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (Radiotherapy + Hyperthermia)
Trial: 7120436
Drug: No-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment control conditions
Trial: 22662729
Drug: Telehealth intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telehealth intervention for self-care management; specific details on dosage and duration not available.
Trial: 22662729
Drug: Telecommunications technologies;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telecommunications technologies; specific details on dosage and duration not available.
Trial: 12135250
Drug: IAS pacing
RxNorm normalized name: magnesium aluminum silicate type Ia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAS pacing in AAIR mode plus antiarrhythmic drugs
Trial: 12135250
Drug: IAS pacing
RxNorm normalized name: magnesium aluminum silicate type Ia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAS pacing in AAIR mode without antiarrhythmic drugs
Trial: 12135250
Drug: Control period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control period (before pacemaker implantation, under antiarrhythmic treatment)
Trial: 12135250
Drug: AAIR pacing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAIR pacing mode without antiarrhythmic drugs
Trial: 10025887
Drug: E. coli
RxNorm normalized name: E. coli antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E. coli L-asparaginase at 10,000 IU/m2 thrice weekly for nine doses
Trial: 10025887
Drug: Epidoxorubicin at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidoxorubicin at 20 mg/m2 weekly for two doses
Trial: 7862469
Drug: Oral transmucosal
RxNorm normalized name: Thrive, 2 mg oral transmucosal gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral transmucosal fentanyl citrate (OTFC) 15 to 20 micrograms/kg
Trial: 2031199
Drug: Vindesin 3
RxNorm normalized name: vindesine
DrugBank: Vindesine (DB00309)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vindesin 3 mg/m2 plus epirubicin 100 mg/m2 plus cyclophosphamide 600 mg/m2 + lonidamine 600 mg/day orally
Trial: 2031199
Drug: Vindesin 3
RxNorm normalized name: vindesine
DrugBank: Vindesine (DB00309)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vindesin 3 mg/m2 plus epirubicin 100 mg/m2 plus cyclophosphamide 600 mg/m2
Trial: 21558074
Drug: Bevacizumab-based therapy
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab-based therapy
Trial: 19247267
Drug: perindopril/indapamide (2/0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: perindopril/indapamide (2/0.625 mg, daily)
Trial: 19247267
Drug: atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol (50 mg, daily)
Trial: 15145099
Drug: Intravenous beta-blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous beta-blockers before PCI (BB+ group)
Trial: 15145099
Drug: No intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intravenous beta-blockers before PCI (BB- group)
Trial: 11187220
Drug: Mivacurium (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium (bolus dose 0.15 mg/kg followed by continuous infusion)
Trial: 11187220
Drug: Atracurium (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium (bolus dose 0.4 mg/kg followed by continuous infusion)
Trial: 3910053
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (G.B.E.) 3 X 40 mg/day
Trial: 3910053
Drug: Nicergoline 5
RxNorm normalized name: nicergoline 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicergoline 5 mg
Trial: 27099272
Drug: 150 min/wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 min/wk of aerobic exercise (low dose)
Trial: 21409296
Drug: Standard self-administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard self-administration of ART
Trial: 16503844
Drug: Nicotine Replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Replacement Therapy (NRT) with free patches and intensive instructions from nurses
Trial: 11059180
Drug: High-chilli diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-chilli diet (approximately 15 g/day) for 3 days.
Trial: 8792944
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin 750 mg bid after 72 hours of intravenous antibiotics (group 1)
Trial: 8792944
Drug: Parenteral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral therapy alone (group 2)
Trial: 8792944
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin (group 1)
Trial: 1298468
Drug: Danggui Funing
RxNorm normalized name: FUNEES KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danggui Funing (DGFN) pill
Trial: 30907929
Drug: Superpower Glass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superpower Glass intervention plus standard of care applied behavioral analysis therapy
Trial: 30907929
Drug: Applied behavioral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Applied behavioral analysis therapy (control)
Trial: 26401577
Drug: Potassium citrate
RxNorm normalized name: Potassium Citrate
DrugBank: Potassium (DB14500)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Potassium citrate (K-citrate), 40 mEq daily for 1 year
Trial: 21410944
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg dose of methotrexate/day for 5 days
Trial: 21410944
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg dose of methotrexate
Trial: 17347500
Drug: Dexamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (8 mg orally) along with conventional opioid treatment
Trial: 17347500
Drug: Conventional opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional opioid treatment
Trial: 14687524
Drug: NO inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO inhalation of 10 ppm
Trial: 10516936
Drug: Controlled-delivery formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-delivery formulation of 240 mg diltiazem (DIL)
Trial: 10516936
Drug: Extended-release formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release formulation of 10 mg felodipine (FEL)
Trial: 10516936
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg amlodipine (AML)
Trial: 1968329
Drug: Good therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Good therapeutic alliance with therapists within the first 6 months of treatment
Trial: 7423602
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of ascorbic acid as one effervescent tablet once daily
Trial: 24443174
Drug: Annual low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Annual low-dose CT screening (CT group)
Trial: 20692602
Drug: Lactoferrin-enriched fermented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactoferrin-enriched fermented milk (200 mg of lactoferrin daily)
Trial: 10353670
Drug: Bolus infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus infusion of 50 mg/kg tranexamic acid at the end of cardiopulmonary bypass (control group)
Trial: 10353670
Drug: Bolus infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus infusion of 50 mg/kg tranexamic acid at the beginning of cardiopulmonary bypass (group A)
Trial: 10353670
Drug: Bolus infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus infusion of 50 mg/kg tranexamic acid at the beginning of cardiopulmonary bypass and continuous infusion of 10 mg/kg per h for 6 h after cardiopulmonary bypass (group B)
Trial: 8745671
Drug: Concomitant radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant radiotherapy with cisplatin (CDDP) 20 mg/m2, 5-fluorouracil (5-FU) 400 mg/m2 (day 1 to day 4), and mitomycin C (MMC) 10 mg/m2 (day 1) for three cycles at days 1, 21, and 42.
Trial: 7028084
Drug: 1% chlortetracycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% chlortetracycline eye ointment
Trial: 7028084
Drug: 1% rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% rifampicin eye ointment
Trial: 28826645
Drug: Oral ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketorolac 20 mg
Trial: 23998970
Drug: Morning-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning-dose group (20 mg controlled-release simvastatin in the morning, placebo in the evening)
Trial: 23998970
Drug: Evening-dose group
RxNorm normalized name: methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Evening-dose group (placebo in the morning, 20 mg controlled-release simvastatin in the evening)
Trial: 21832863
Drug: Azelastine nasal
RxNorm normalized name: azelastine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine nasal spray 0.1% (ANS)
Trial: 21832863
Drug: Levocabastine nasal
RxNorm normalized name: levocabastine Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocabastine nasal spray 0.05% (LNS)
Trial: 9063764
Drug: 1,500 mg
RxNorm normalized name: garlic 1,500 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,500 mg L-arginine and 1,500 mg L-lysine ingestion followed by resistance exercise (Trial B)
Trial: 9063764
Drug: 1,500 mg
RxNorm normalized name: garlic 1,500 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,500 mg L-arginine and 1,500 mg L-lysine ingestion without exercise (Trial C)
Trial: 3101535
Drug: Ro 15-1788
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 15-1788 (0.5 to 2.0 mg)
Trial: 3101535
Drug: Ro 15-1788
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 15-1788 (0.3 to 0.8 mg)
Trial: 30455091
Drug: Standard physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard physical therapy interventions (manual therapy and exercise)
Trial: 30455091
Drug: Standard physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard physical therapy and trigger point dry needling
Trial: 30455091
Drug: Standard physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard physical therapy and sham trigger point dry needling
Trial: 26995298
Drug: Escitalopram, Sertraline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram, Sertraline, or Venlafaxine extended-release (8 weeks treatment)
Trial: 26995298
Drug: Matched healthy
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched healthy participants (no medication or intervention)
Trial: 25498992
Drug: Home telemonitoring
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home telemonitoring (n=47); patients measured body weight, blood pressure, pulse, and answered symptom-related questions weekly, reporting to a heart failure nurse via a mobile app.
Trial: 25498992
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n=47); received multidisciplinary treatment according to standard practices.
Trial: 22749594
Drug: 23-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23-valent pneumococcal polysaccharide vaccine and/or 7-valent pneumococcal conjugate vaccine (PCV7)
Trial: 20031392
Drug: Oral clodronate
RxNorm normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral clodronate 1600 mg/d